前列腺素E1治疗肺源性心脏病54例疗效观察

1997年6月～2000年12月，我院在一般常规治疗基础上加用前列腺素E1(PGE1)治疗肺源性心脏病(肺心病)54例，疗效满意。     

前列腺素E1联合黄芪注射液治疗肺源性心脏病急性加重期疗效观察

我院自2003年1月-2004年9月共收治肺源性心脏病急性加重期患者55例,应用前列腺素E1与黄芪注射液联合治疗,效果满意,现报道如下。     

超声雾化硫酸镁治疗慢性肺源性心脏病的疗效观察

选择我院2005年12月-2007年7月住院的200例慢性肺源性心脏病患者，对其随机分组并观察超声雾化硫酸镁治疗慢性肺源性心脏病的治疗效果，现报告如下。[第一段]     

丹红注射液治疗慢性肺源性心脏病急性加重期临床疗效观察

探讨丹红注射液治疗慢性肺源性心脏病急性加重期的临床疗效。将70例慢性肺源性心脏病急性加重期患者随机分为观察组和对照组各35例,所有患者均给予常规抗右心衰、祛痰、解痉平喘、控制感染、维持电解质和酸碱平衡等治疗。观察组在此基础上加用丹红注射液治疗,连续治疗14d后对比观察两组临床疗效和血气分析指标。观察组总有效率为91.43%,显著高于对照组的71.43%,差异有统计学意义(P<0.05);与治疗前比较,两组治疗后Pa O2均显著升高,Pa CO2显著降低,差异有统计学意义(P<0.05);治疗后观察组Pa O2显著高于对照组,Pa CO2显著低于对照组,差异有统计学意义(P<0.05)。丹红注射液治疗慢性肺源性心脏病急性加重期具有较好的疗效,可以显著改善血氧供给,值得临床推广。     

前列腺素E1治疗肺源性心脏病急性加重期疗效观察

前列腺素E1(PGE1)静脉滴注可有效地改善血液黏度，扩张肺血管，降低肺动脉高压。我们用PGE。治疗肺源性心脏病(肺心病)，观察其对肺心病患者血液流变学及肺血流动力学的影响。     

血塞通治疗慢性肺源性心脏病急性加重期的疗效观察

目的血塞通注射液治疗慢性肺源性心脏病急性加重期的疗效观察与评估。方法将慢性肺心病急性加重期的患者42例随机分为治疗组和对照组，治疗组（T组）25例采用血塞通注射液加综合治疗；对照组（N组）17例单纯采用综合治疗。结果治疗组疗效明显好于对照组，两组差异有显著性（P〈0．05）。结论血塞通注射液治疗慢性肺心病急性加重期的疗效明显。     

前列腺素E1对肺源性心脏病患者肺血流动力学的影响

目的：观察静脉滴注前列腺素E1对肺源性心脏病（肺心病）肺血流动力学及血气的影响。方法：对34例肺民主病患者连续10天静脉滴注前列腺素E1200μg/d。治疗前后用彩色多普勒超声诊断仪检测肺血流动力学指标并作血气分析。结果：前列腺素E1治疗后肺动脉平均压（mPAR)显著降低（P＜0.01),右心室射血前期（RPEP）、右心室射血时间（RVET）均有改善,PaCO2下降,SaO2上升（P＜0.05);PaO2无明显改变。结论：前列腺素E1可以降低肺心病患者的肺动脉高压,改善右心功能并减轻二氧化碳潴留。     

BiPAP呼吸机治疗慢性肺源性心脏病临床疗效观察

应用美国伟康公司生产双水平正压通气（BiPAP）呼吸机（STD-30型）连接鼻罩或口鼻面罩治疗慢性肺源性心脏病（肺心病），并进行对照分析，报告如下。     

生脉注射液治疗慢性肺源性心脏病急性加重期32例疗效观察

目的：观察生脉注射液配合常规西药治疗慢性肺源性心脏病急性加重期的疗效。方法：选择64例患者随机分为两组，治疗组在常规西药治疗的基础上用生脉注射液40ml溶于5％葡萄糖注射液250ml缓慢静脉滴注，25－40滴／min，qd,7-10d为1个疗程，对照组采用常规西药治疗，进行系统的临床观察。结论：生脉注射液在治疗慢性肺源性心脏病急性加重期的过程中，对改善病人临床症状的效果较单用西药常规治疗显著。     

前列腺素E1联合硫酸镁在肺心病急性加重期应用中的临床研究

目的 探讨前列腺素E1注射液和硫酸镁注射液联用对肺心病急性加重期的临床疗效及作用机制.方法 将2007年6月至2008年5月广州市红十字会医院急诊科留观室收治的53例肺心病急性加重期患者,随机分为治疗组28例、对照组25例.2组均给予低流量吸氧、祛痰止咳、抗感染、解痉平喘、强心利尿等综合治疗,治疗组在综合治疗基础上加用前列腺素E1注射液10 ml、25%硫酸镁注射液10 ml,疗程2周.观察2组患者治疗后临床症状改善状况及治疗前后血气分析的改变.结果 2组患者临床疗效总有效率分别为89.3%(25/28)和76.0%(18/25),治疗组疗效优于对照组(χ2=1.87,P<0.05);治疗组治疗前PaO2(8.36±2.28)kPa、PaCO2(9.31±3.41)kPa、全血黏度(12.12±0.45)mPa、纤维蛋白原(5.32±1.16)g/L,对照组治疗前PaO2(8.27±1.92)kPa、PaCO2(9.43±2.82)kPa、全血黏度(12.32±0.52)mPa·s、纤维蛋白原(5.18±1.23)g/L;治疗组治疗后PaO2(10.52±2.12)kPa、PaCO2(7.63±1.62)kPa、全血黏度(7.42±0.36)mPa、纤维蛋白原(3.21±0.97)g/L,对照组治疗后PaO2(9.15±1.83)kPa,PaCO2(8.54±1.67)kPa、全血黏度(11.92±0.31)mPa·s、纤维蛋白原(4.76±2.14)g/L;2组患者治疗后PaO2、PaCO2、全血黏度及纤维蛋白原均有改善(P均<0.05),但治疗组血气分析各项观察指标的改善优于对照组(P均<0.05).结论 前列腺素E1注射液和硫酸镁注射液联用,能降低肺动脉压,减轻右心室后负荷,扩张气管平滑肌、改善通气障碍,可改善肺心病急性加重期的PaO2、PaCO2,对肺心病急性加重期有较好的临床疗效.     

前列腺素E1联合硫酸镁在肺心病急性加重期应用中的临床研究

Objective To study the curative effect and medchanism of action about prostaglandin E1 and magnesium sulfate in the treatment of chronic pulmonary heart disease in the aggravation period. Methods Fifty-three patients with chronic pulmonary heart disease in the aggravation period were accepted emergencyward in the Guangzhou Red Cross Hospital during June 2007 to May 2008,they were randomly divided into the treatment group (28 case) and control group (25 case) . Both groups were given low flux breathe in oxygen and dissipate phlegm and relieve a cough and resist infection and spasmo]ysis and calm down asthma and strive heart and diuresis colligate therapy. Mean while,patients in the treatment group,beside the colligate therapy,were treated with prostaglandin E1 10 ml and magnesium sulfate 10 ml ,the course of treatment lasted 2 weeks. Then we investigate the amelioration of clinical symptom and alteration of blood gas analysis in the two groups before and after the treatment. Results The rate of clinical efficacy were 89.3% (25/28) and 76.0% (18/25),with superiority in the treatment group (χ2=1.87,P<0.05) . Whole blood viscosity,fibrinogen,PaO2 and PaCO2 were improved in both groups,amelioration of blood gas analysis observation superiority in the treatment group compared with control group (P<0.05). Conclu-sions Prostaglandin E1 and magnesium sulfate can depress pulmonary artery pressure and abate the afterload of right ventricle,which have better treatment effect in chronic pulmonary heart disease in the aggravation period.     

前列腺素E1联合硫酸镁在肺心病急性加重期应用中的临床研究

Objective To study the curative effect and medchanism of action about prostaglandin E1 and magnesium sulfate in the treatment of chronic pulmonary heart disease in the aggravation period. Methods Fifty-three patients with chronic pulmonary heart disease in the aggravation period were accepted emergencyward in the Guangzhou Red Cross Hospital during June 2007 to May 2008,they were randomly divided into the treatment group (28 case) and control group (25 case) . Both groups were given low flux breathe in oxygen and dissipate phlegm and relieve a cough and resist infection and spasmo]ysis and calm down asthma and strive heart and diuresis colligate therapy. Mean while,patients in the treatment group,beside the colligate therapy,were treated with prostaglandin E1 10 ml and magnesium sulfate 10 ml ,the course of treatment lasted 2 weeks. Then we investigate the amelioration of clinical symptom and alteration of blood gas analysis in the two groups before and after the treatment. Results The rate of clinical efficacy were 89.3% (25/28) and 76.0% (18/25),with superiority in the treatment group (χ2=1.87,P<0.05) . Whole blood viscosity,fibrinogen,PaO2 and PaCO2 were improved in both groups,amelioration of blood gas analysis observation superiority in the treatment group compared with control group (P<0.05). Conclu-sions Prostaglandin E1 and magnesium sulfate can depress pulmonary artery pressure and abate the afterload of right ventricle,which have better treatment effect in chronic pulmonary heart disease in the aggravation period.     

前列腺素E1联合硫酸镁在肺心病急性加重期应用中的临床研究

Objective To study the curative effect and medchanism of action about prostaglandin E1 and magnesium sulfate in the treatment of chronic pulmonary heart disease in the aggravation period. Methods Fifty-three patients with chronic pulmonary heart disease in the aggravation period were accepted emergencyward in the Guangzhou Red Cross Hospital during June 2007 to May 2008,they were randomly divided into the treatment group (28 case) and control group (25 case) . Both groups were given low flux breathe in oxygen and dissipate phlegm and relieve a cough and resist infection and spasmo]ysis and calm down asthma and strive heart and diuresis colligate therapy. Mean while,patients in the treatment group,beside the colligate therapy,were treated with prostaglandin E1 10 ml and magnesium sulfate 10 ml ,the course of treatment lasted 2 weeks. Then we investigate the amelioration of clinical symptom and alteration of blood gas analysis in the two groups before and after the treatment. Results The rate of clinical efficacy were 89.3% (25/28) and 76.0% (18/25),with superiority in the treatment group (χ2=1.87,P<0.05) . Whole blood viscosity,fibrinogen,PaO2 and PaCO2 were improved in both groups,amelioration of blood gas analysis observation superiority in the treatment group compared with control group (P<0.05). Conclu-sions Prostaglandin E1 and magnesium sulfate can depress pulmonary artery pressure and abate the afterload of right ventricle,which have better treatment effect in chronic pulmonary heart disease in the aggravation period.     

前列腺素E1联合硫酸镁在肺心病急性加重期应用中的临床研究

Objective To study the curative effect and medchanism of action about prostaglandin E1 and magnesium sulfate in the treatment of chronic pulmonary heart disease in the aggravation period. Methods Fifty-three patients with chronic pulmonary heart disease in the aggravation period were accepted emergencyward in the Guangzhou Red Cross Hospital during June 2007 to May 2008,they were randomly divided into the treatment group (28 case) and control group (25 case) . Both groups were given low flux breathe in oxygen and dissipate phlegm and relieve a cough and resist infection and spasmo]ysis and calm down asthma and strive heart and diuresis colligate therapy. Mean while,patients in the treatment group,beside the colligate therapy,were treated with prostaglandin E1 10 ml and magnesium sulfate 10 ml ,the course of treatment lasted 2 weeks. Then we investigate the amelioration of clinical symptom and alteration of blood gas analysis in the two groups before and after the treatment. Results The rate of clinical efficacy were 89.3% (25/28) and 76.0% (18/25),with superiority in the treatment group (χ2=1.87,P<0.05) . Whole blood viscosity,fibrinogen,PaO2 and PaCO2 were improved in both groups,amelioration of blood gas analysis observation superiority in the treatment group compared with control group (P<0.05). Conclu-sions Prostaglandin E1 and magnesium sulfate can depress pulmonary artery pressure and abate the afterload of right ventricle,which have better treatment effect in chronic pulmonary heart disease in the aggravation period.     

前列腺素E1联合硫酸镁在肺心病急性加重期应用中的临床研究

Objective To study the curative effect and medchanism of action about prostaglandin E1 and magnesium sulfate in the treatment of chronic pulmonary heart disease in the aggravation period. Methods Fifty-three patients with chronic pulmonary heart disease in the aggravation period were accepted emergencyward in the Guangzhou Red Cross Hospital during June 2007 to May 2008,they were randomly divided into the treatment group (28 case) and control group (25 case) . Both groups were given low flux breathe in oxygen and dissipate phlegm and relieve a cough and resist infection and spasmo]ysis and calm down asthma and strive heart and diuresis colligate therapy. Mean while,patients in the treatment group,beside the colligate therapy,were treated with prostaglandin E1 10 ml and magnesium sulfate 10 ml ,the course of treatment lasted 2 weeks. Then we investigate the amelioration of clinical symptom and alteration of blood gas analysis in the two groups before and after the treatment. Results The rate of clinical efficacy were 89.3% (25/28) and 76.0% (18/25),with superiority in the treatment group (χ2=1.87,P<0.05) . Whole blood viscosity,fibrinogen,PaO2 and PaCO2 were improved in both groups,amelioration of blood gas analysis observation superiority in the treatment group compared with control group (P<0.05). Conclu-sions Prostaglandin E1 and magnesium sulfate can depress pulmonary artery pressure and abate the afterload of right ventricle,which have better treatment effect in chronic pulmonary heart disease in the aggravation period.     

前列腺素E1联合硫酸镁在肺心病急性加重期应用中的临床研究

Objective To study the curative effect and medchanism of action about prostaglandin E1 and magnesium sulfate in the treatment of chronic pulmonary heart disease in the aggravation period. Methods Fifty-three patients with chronic pulmonary heart disease in the aggravation period were accepted emergencyward in the Guangzhou Red Cross Hospital during June 2007 to May 2008,they were randomly divided into the treatment group (28 case) and control group (25 case) . Both groups were given low flux breathe in oxygen and dissipate phlegm and relieve a cough and resist infection and spasmo]ysis and calm down asthma and strive heart and diuresis colligate therapy. Mean while,patients in the treatment group,beside the colligate therapy,were treated with prostaglandin E1 10 ml and magnesium sulfate 10 ml ,the course of treatment lasted 2 weeks. Then we investigate the amelioration of clinical symptom and alteration of blood gas analysis in the two groups before and after the treatment. Results The rate of clinical efficacy were 89.3% (25/28) and 76.0% (18/25),with superiority in the treatment group (χ2=1.87,P<0.05) . Whole blood viscosity,fibrinogen,PaO2 and PaCO2 were improved in both groups,amelioration of blood gas analysis observation superiority in the treatment group compared with control group (P<0.05). Conclu-sions Prostaglandin E1 and magnesium sulfate can depress pulmonary artery pressure and abate the afterload of right ventricle,which have better treatment effect in chronic pulmonary heart disease in the aggravation period.     

前列腺素E1联合硫酸镁在肺心病急性加重期应用中的临床研究

Objective To study the curative effect and medchanism of action about prostaglandin E1 and magnesium sulfate in the treatment of chronic pulmonary heart disease in the aggravation period. Methods Fifty-three patients with chronic pulmonary heart disease in the aggravation period were accepted emergencyward in the Guangzhou Red Cross Hospital during June 2007 to May 2008,they were randomly divided into the treatment group (28 case) and control group (25 case) . Both groups were given low flux breathe in oxygen and dissipate phlegm and relieve a cough and resist infection and spasmo]ysis and calm down asthma and strive heart and diuresis colligate therapy. Mean while,patients in the treatment group,beside the colligate therapy,were treated with prostaglandin E1 10 ml and magnesium sulfate 10 ml ,the course of treatment lasted 2 weeks. Then we investigate the amelioration of clinical symptom and alteration of blood gas analysis in the two groups before and after the treatment. Results The rate of clinical efficacy were 89.3% (25/28) and 76.0% (18/25),with superiority in the treatment group (χ2=1.87,P<0.05) . Whole blood viscosity,fibrinogen,PaO2 and PaCO2 were improved in both groups,amelioration of blood gas analysis observation superiority in the treatment group compared with control group (P<0.05). Conclu-sions Prostaglandin E1 and magnesium sulfate can depress pulmonary artery pressure and abate the afterload of right ventricle,which have better treatment effect in chronic pulmonary heart disease in the aggravation period.     

前列腺素E1联合硫酸镁在肺心病急性加重期应用中的临床研究

Objective To study the curative effect and medchanism of action about prostaglandin E1 and magnesium sulfate in the treatment of chronic pulmonary heart disease in the aggravation period. Methods Fifty-three patients with chronic pulmonary heart disease in the aggravation period were accepted emergencyward in the Guangzhou Red Cross Hospital during June 2007 to May 2008,they were randomly divided into the treatment group (28 case) and control group (25 case) . Both groups were given low flux breathe in oxygen and dissipate phlegm and relieve a cough and resist infection and spasmo]ysis and calm down asthma and strive heart and diuresis colligate therapy. Mean while,patients in the treatment group,beside the colligate therapy,were treated with prostaglandin E1 10 ml and magnesium sulfate 10 ml ,the course of treatment lasted 2 weeks. Then we investigate the amelioration of clinical symptom and alteration of blood gas analysis in the two groups before and after the treatment. Results The rate of clinical efficacy were 89.3% (25/28) and 76.0% (18/25),with superiority in the treatment group (χ2=1.87,P<0.05) . Whole blood viscosity,fibrinogen,PaO2 and PaCO2 were improved in both groups,amelioration of blood gas analysis observation superiority in the treatment group compared with control group (P<0.05). Conclu-sions Prostaglandin E1 and magnesium sulfate can depress pulmonary artery pressure and abate the afterload of right ventricle,which have better treatment effect in chronic pulmonary heart disease in the aggravation period.     

前列腺素E1联合硫酸镁在肺心病急性加重期应用中的临床研究

Objective To study the curative effect and medchanism of action about prostaglandin E1 and magnesium sulfate in the treatment of chronic pulmonary heart disease in the aggravation period. Methods Fifty-three patients with chronic pulmonary heart disease in the aggravation period were accepted emergencyward in the Guangzhou Red Cross Hospital during June 2007 to May 2008,they were randomly divided into the treatment group (28 case) and control group (25 case) . Both groups were given low flux breathe in oxygen and dissipate phlegm and relieve a cough and resist infection and spasmo]ysis and calm down asthma and strive heart and diuresis colligate therapy. Mean while,patients in the treatment group,beside the colligate therapy,were treated with prostaglandin E1 10 ml and magnesium sulfate 10 ml ,the course of treatment lasted 2 weeks. Then we investigate the amelioration of clinical symptom and alteration of blood gas analysis in the two groups before and after the treatment. Results The rate of clinical efficacy were 89.3% (25/28) and 76.0% (18/25),with superiority in the treatment group (χ2=1.87,P<0.05) . Whole blood viscosity,fibrinogen,PaO2 and PaCO2 were improved in both groups,amelioration of blood gas analysis observation superiority in the treatment group compared with control group (P<0.05). Conclu-sions Prostaglandin E1 and magnesium sulfate can depress pulmonary artery pressure and abate the afterload of right ventricle,which have better treatment effect in chronic pulmonary heart disease in the aggravation period.